Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125308391 | 12530839 | 1 | I | 20160305 | 20160629 | 20160706 | 20160706 | EXP | CH-SM-2016-05268 | CH-PFIZER INC-2016324564 | PFIZER | 69.00 | YR | F | Y | 0.00000 | 20160706 | MD | CH | CH |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125308391 | 12530839 | 1 | PS | DIFLUCAN | FLUCONAZOLE | 1 | Oral | 400 MG, WEEKLY | Y | 19949 | 400 | MG | CAPSULE, HARD | /wk | |||||
| 125308391 | 12530839 | 2 | SS | MEPHANOL | ALLOPURINOL | 1 | Oral | Y | 0 | 300 | MG | QD | |||||||
| 125308391 | 12530839 | 3 | I | ZOCOR | SIMVASTATIN | 1 | Oral | 40 MG, 1X/DAY | Y | 0 | 40 | MG | QD | ||||||
| 125308391 | 12530839 | 4 | I | SANDIMMUNE | CYCLOSPORINE | 1 | Oral | 50 MG, 2X/DAY | Y | N | 0 | 50 | MG | BID | |||||
| 125308391 | 12530839 | 5 | SS | VIPIDIA | ALOGLIPTIN BENZOATE | 1 | Oral | 12.5 MG, 1X/DAY | Y | 0 | 12.5 | MG | QD | ||||||
| 125308391 | 12530839 | 6 | C | PANTOPRAZOL | PANTOPRAZOLE SODIUM | 1 | 0 | ||||||||||||
| 125308391 | 12530839 | 7 | C | NOPIL | SULFAMETHOXAZOLETRIMETHOPRIM | 1 | 0 | ||||||||||||
| 125308391 | 12530839 | 8 | C | VALTREX | VALACYCLOVIR HYDROCHLORIDE | 1 | 0 | ||||||||||||
| 125308391 | 12530839 | 9 | C | AMLODIPIN | AMLODIPINE BESYLATE | 1 | 0 | ||||||||||||
| 125308391 | 12530839 | 10 | C | IRBESARTAN AND HYDROCHLOROTHIAZIDE | HYDROCHLOROTHIAZIDEIRBESARTAN | 1 | 0 | ||||||||||||
| 125308391 | 12530839 | 11 | C | ELTROXIN | LEVOTHYROXINE | 1 | Oral | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 125308391 | 12530839 | 1 | Prophylaxis |
| 125308391 | 12530839 | 3 | Hypercholesterolaemia |
| 125308391 | 12530839 | 4 | Aplastic anaemia |
| 125308391 | 12530839 | 5 | Type 2 diabetes mellitus |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 125308391 | 12530839 | HO |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 125308391 | 12530839 | Acute kidney injury | |
| 125308391 | 12530839 | Drug-induced liver injury | |
| 125308391 | 12530839 | Hepatocellular injury | |
| 125308391 | 12530839 | Labelled drug-drug interaction medication error | |
| 125308391 | 12530839 | Rhabdomyolysis |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 125308391 | 12530839 | 1 | 201602 | 201604 | 0 | |
| 125308391 | 12530839 | 2 | 201602 | 20160408 | 0 | |
| 125308391 | 12530839 | 3 | 20160305 | 20160407 | 0 | |
| 125308391 | 12530839 | 4 | 201602 | 20160408 | 0 | |
| 125308391 | 12530839 | 5 | 201602 | 20160408 | 0 |